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WHAT THIS PAPER ADDS
 Antibiotic impregnation of vascular grafts prior to implantation for local antibiotic release remains an adjuvant measure against
bacterial colonisation. However, controversial results between different antibiotic agents have been established. Major drawbacks
remain the limited antibacterial effect against high-virulent Gram-negative micro-organisms, the selective antibacterial activity
(e.g., against only Gram-positive micro-organisms) and the rapid development of bacterial resistance against antibiotics.
 This study introduces nebacetin as an effective and safe antibiotic agent for vascular graft impregnation against both Gram-positive
and -negative micro-organisms. In this context, impregnationwith nebacetin will contribute to reduction of perioperative vascular
graft infections and optimisation of their challenging treatment.a r t i c l e i n f o
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Objective: To compare the in vitro efﬁcacy of graft impregnation with nebacetin versus rifampin versus
daptomycin against vascular graft infections caused by Staphylococcus epidermidis and Staphylococcus
aureus and nebacetin versus rifampin against Pseudomonas aeruginosa and Escherichia coli.
Materials: Twenty-three Dacron-grafts (1 cm2) for each micro-organism were microbiologically tested and
eight grafts per antibiotic underwent viability tests againsthumanumbilical vein endothelial cells (ECs). Fifteen
grafts (5/antibiotic agent) underwent 15 min impregnation and contamination with 4 ml bacterial solution
(optical density (OD600 nm): 0.20  0.02). After 24-h-incubation, all grafts were washed with phosphate-
buffered saline and underwent soniﬁcation to release viable adherent bacteria. OD600 nm of the solution was
measured. Afterwards, six 1:10 dilution steps took place and colony-forming units (CFUs) were counted.
Results: Nebacetin showed comparable efﬁcacy to daptomycin against Gram-positive bacteria. Both
eradicated more efﬁciently S. epidermidis than rifampin (daptomycin:0, rifampin:5  7.3,
nebacetin:0 CFU ml1, P ¼ 0.0003). All antibiotics showed comparable antibacterial activity against
S. aureus. Nebacetin was more efﬁcient than rifampin to eradicate Gram-negative organisms
(P. aeruginosa: rifampin:1308  252, nebacetin:8  8 CFU ml1, P ¼ 0.01, E. coli: rifampin:294  159,
nebacetin:0.2  0.5 CFU ml1, P ¼ 0.001), while only rifampin was toxic against ECs
(daptomycin:30.88  5.44, rifampin:5.13  5.08, nebacetin:28.50  3.82 ECs/ﬁeld, P ¼ 0.0003).
Conclusions: Nebacetin showed excellent in vitro antibacterial activity against both Gram-positive
and -negative pathogens representing an effective candidate for vascular graft impregnation.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.eting of the European Society
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ciety for Vascular Surgery. PublishInfection of surgical implants represents a devastating compli-
cation with essential clinical and economical impact.1 In vascular
surgery, the average rate of graft infections is about 4% with high
morbidity and mortality rates (10e75%) and an estimated average
cost of combined medical and surgical treatment amounted to
V30 000.1e4 Besides, the changing epidemiology of infections anded by Elsevier Ltd. All rights reserved.
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antibiotic resistance of otherwise harmless micro-organisms such
as Staphylococcus aureus and Staphylococcus epidermidis.2,3 Addi-
tionally, vascular graft infections (VGIs) caused by Gram-negative
organisms such as Pseudomonas aeruginosa are associated with
high reinfection rates and poor survival outcomes.4,5
Notwithstanding on late VGI, the majority of early VGI is caused
by inoculation of bacteria at the time of surgery despite perioper-
ative antibiotic prophylaxis.2 It is well known that, in this case,
intravenous antibiotic therapy is unable to reach a sufﬁcient topical
tissue concentration to penetrate the bioﬁlm which protects the
embedded bacteria.6 Therefore, impregnation of vascular pros-
theses with antibiotic agents prior to implantation for local anti-
biotic release seems advantageous.6e8 However, controversial
results about the most effective antibiotic agent have been pub-
lished. Gold standard for graft impregnation or coating remains
rifampin.8 Currently, daptomycin showed excellent antibacterial
effect on bioﬁlm-associated cells, especially when combined with
rifampin.8 However, our clinical experience with another antibiotic
agent, which combines neomycin and bacitracin (i.e., nebacetin),
for the treatment of VGI revealed encouraging results as well.9,10
We hypothesised that nebacetin is more efﬁcient than dapto-
mycin or rifampin for the in vitro prevention of VGI. Thus, we
compared all three antibiotics in an experimental model of graft
infection caused by S. epidermidis, S. aureus (as Gram-positive
pathogens) and nebacetin versus rifampin for graft infection
caused by P. aeruginosa and Escherichia coli (as Gram-negative
pathogens).
Materials and Methods
Bacterial strain
The bacterial isolates in this study were 20044DSMZ for
S. epidermidis, 20231DSMZ for S. aureus, ATCC27853 for P. aeruginosa
and 1103DSMZ for E. coli. Strains were sub-cultured on tryptic soy
agar according to the recommendations of the German Collection of
Microorganisms and Cell Cultures GmbH (www.dsmz.de). The
optical density (OD600 nm), used for graft contamination, amounted
to 0.20. This OD corresponds to 1106 colony-forming units (CFUs)
per millilitre for S. epidermidis, 1  108 CFU ml1 for S. aureus,
1 107 CFU ml1 for P. aeruginosa and 1 107 CFU for E. coli.
Antibiotic agents
Sterile solution preparation of daptomycin 500 mg (Cubicin,
Cubist Pharmaceuticals, Inc, Lexington, USA), rifampin 600 mg
(Eremfat, Riemser Arzneimittel, Greifswald, Germany) and neba-
cetin 100 ml (bacitracin 250 IU, neomycin sulphate 5000 IU,
Baneocin pro instillatione, Sandoz, Kundl, Switzerland) was per-
formed according to manufacturer’s instructions. The antibiotic
concentrations were the same with the respective concentrations
achievable in humans.
Grafts
Commercially available double-woven velour vascular grafts
(Unigraft, BBraun, Melsungen, Germany) made of ﬁne polyester
ﬁbres and coated with absorbable modiﬁed gelatine were used. The
grafts were processed to 1  1 cm pieces under aseptic conditions.
Experimental protocol
The grafts were processed to a total number of 129 pieces
(n ¼ 129). Twenty-three 1-cm2 grafts were used for themicrobiological investigations against S. aureus and S. epidermidis,
respectively, 18 grafts (daptomycin was not tested for Gram-
negative micro-organisms) against P. aeruginosa and E. coli,
respectively (n ¼ 82 grafts) and eight grafts per antibiotic agent
(n¼ 32 grafts) for viability tests against human umbilical cord vein-
derived endothelial cells (ECs). Additionally, we used ﬁve grafts per
antibiotic agent (n ¼ 15) to assess the amount (A) of the antibiotic
that has been impregnated into each graft (A ¼ WAI e WBI, WAI:
weight of graft after impregnation and WBI: weight before
impregnation).
An overview of our experiment protocol is illustrated in Fig. 1. In
detail, the impregnation of the grafts (phase I) was done in 50-ml
Falcon tubes containing the antibiotic solution and lasted 15 min
for each specimen. The impregnation time was adopted from
clinical practice. Then, 4 ml of tryptic soy broth (TSB, Oxoid, UK)
were added under aseptic conditions to a Petri dish and contami-
nated with bacteria (OD600 nm:0.20 0.02). Each impregnated graft
was placed in a separate Petri dish.
In the second phase, ﬁve grafts (n ¼ 5) per antibiotic agent were
placed into the incubator (37 C, 5%CO2) for 24 h. Two untreated
grafts for each micro-organism (n ¼ 2, positive control), one
untreated graft without contamination (n¼ 1, negative control) and
a Petri dish only with TSB (to assess our medium sterility) were
used as controls. Three grafts (n ¼ 3) for each antibiotic were also
placed into the incubator for 24 h and used for the assessment of
the respective bioﬁlms through scanning electron microscopy
(SEM). SEM evaluation underwent additionally one untreated graft
withmicro-organism (n¼ 1, positive control) and one graft without
micro-organism or antibiotic (n ¼ 1, negative control). After incu-
bation, all grafts were removed and washed three times in 20-ml
phosphate-buffered saline (PBS) from GIBCO (Darmstadt, Ger-
many) to eliminate unbound bacteria. Thereafter, viable adherent
bacteria were released by soniﬁcation on low power (100%) for
20 min. OD600 nm of PBS containing the dislodged bacteria was
measured over again. We performed six 1:10 dilution steps of the
solution and 100 mL of each dilution were plated onto TSB agar
plates. All plates were incubated overnight at 37 C and colonies
were visually identiﬁed and counted.
The third phase included viability tests for ECs. Regional ethics
committee approved the cell isolation from healthy new-born
donors as previously described11 and their culture at 5%CO2 and
37 C and in supplemented endothelial growth medium No.2
(Lonza, Basel, Switzerland) in gelatin-coated (1%) ﬂasks (Nunc,
Langenselbold, Germany). Upon conﬂuence, cells were passaged
with trypsin/ethylenediaminetetraacetic acid and the total cell
number was determined by using a Casy electric ﬁeld multi-
channel cell counter (Roche Innovatis Reutlingen, Germany).
Subsequently, the desired number of cells was seeded into gelatine-
coated 24-well culture plates for the experiment.
On the day of experiment, the cell culture mediumwas renewed
and the antibiotic solutions were freshly prepared. Twenty-four
grafts (n ¼ 24) were impregnated with antibiotic (eight grafts per
antibiotic) and eight untreated grafts were placed in PBS serving as
control group. After 15 min of antibiotic impregnation, graft pieces
were transferred into the wells of the cell culture dishes and
incubated for 24 h (37 C, 5%CO2) until the cell viability analysis was
performed. The number of viable ECs was assessed by ﬂuorescent-
live cell imaging using calcein acetoxymethyl ester e a green
ﬂuorescent dye that stains living cells via cleavage by non-speciﬁc
intracellular esterases. The graft pieces as well as the mediumwere
discarded and each well was washed 3 times with PBS. Then, ECs
were stained with calcein acetoxymethyl ester (Invitrogen) at
a ﬁnal concentration of 2 mM for 30 min at 37 C. Next, the staining
solution was replaced with calcium-containing PBS and photomi-
crographs were taken using an AxioCam-MRm camera (Zeiss, Jena,
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AxioVision software. For each well, photomicrographs of ﬁve
random low power ﬁelds were taken and the number of adherent
viable cells was determined by counting the positively stained ECs
per microscopic ﬁeld.
Scanning electron microscopy
The grafts for SEMwere alsowashed three times inPBS inorder to
remove planktonic cell cultures (suspended micro-organisms) from
Petri dish, whichmight cause diagnostic bias in bioﬁlm observation.
All grafts were ﬁxed in 2.5% glutaraldehyde and sodiumcodylate
buffer (0.2 M, pH 7.3) and transported in 50-ml Falcon tubes into
a sterile container to laser centre, and 24 h laterwere observed in the
SEM (FEI Quanta 400). This microscope increases its imaging capa-
bilities with high-resolution high-, low- and extended low-vacuum
(ESEM) secondary electron imaging. In our experiment, a voltage of
30 kV and a resolution of 1 nmwere used. Our goal was a descriptive
assessment of bioﬁlms of each micro-organism and the antibiotic
effect on bioﬁlm formation supportively to our microbiological
results. ‘Microbial bioﬁlm’ was deﬁned as populations of micro-
organisms that are concentrated at an interface (in this case solid)
and typically surrounded by an extracellular polymeric substance.12
Statistical analysis
All analyses were performed and graphs were created with
GraphPad 5.0d Software, Inc. Quantitative culture results wereFigure 1. Schematic overview of oupresented as arithmetic mean standard deviation (SD). This study
could not be blinded due to the orange colour of rifampin. Sample
sizes were estimated through Mead’s resource equation.13
Comparisons between two groups were performed using
ManneWhitney test. We did not perform any normality test to
assess Gaussian distributions due to the small samples being
compared. Thus, comparison between three groups (daptomycin
vs. rifampin vs. nebacetin) was done using KruskaleWallis’ analysis
of variance.14 Differences at P < 0.05 were considered statistically
signiﬁcant.
Results
Amount of impregnated antibiotic
According to the aforementioned formula (A ¼WAI e WBI), the
mean amount of the impregnated antibiotic within the grafts was
30  5 mg for daptomycin, 35  4 mg for rifampin and 28  8 mg
for nebacetin. Comparably, in the commercially available suscep-
tibility tests for ordinary drug resistance the loaded amount of
these antibiotics is 0.03 mg ml1 for daptomycin, 0.01 mg ml1 for
neomycin and bacitracin, respectively, and 0.005 mg ml1 for
rifampin.
Staphylococcus epidermidis
OD600 nm after 24-h incubation and prior to soniﬁcation: Mean
OD600 was 0.04 (0.01) in the daptomycin group (DG), 0.18  0.02r experimental study protocol.
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(NG) [P < 0.007, Kruskal Wallis statistic (KWS): 9.9].
OD600 nm and bacterial count after soniﬁcation: Mean OD after
soniﬁcation is presented in Fig. 2A. The average bacterial count was
measured after second and sixth dilution. Regarding second dilu-
tion, bacterial count was 0 CFU ml1 in the DG and the NG and
5  7.3 CFU ml1 in the RG (P ¼ 0.0003, KWS: 16.4). The positive
control grafts showed 3332  662 CFU ml1. After sixth dilution,
average bacteria count was 0 CFU ml1 in the DG and the NG and
0.2  0.4 CFU ml1 in the RG (P ¼ 0.12, KWS:4.2). The positive
control grafts showed 64  30 CFU ml1 after sixth dilution.
Negative controls as well as medium remained negative for micro-
organisms after all dilution steps.
Staphylococcus aureus
OD600 nm after 24-h incubation and prior to soniﬁcation: After
24-h incubationwith S. aureus, mean OD600 was 0.4 0.1 in the DG,
0.6  0.1 in the RG and 0.3  0.4 in the NG (P ¼ 0.06, KWS:5.7).
OD600 nm and bacterial count after soniﬁcation: After soniﬁca-
tion, mean OD600 is presented in Fig. 2B. The average bacterial
count after second as well as sixth dilution was 0 CFU ml1 in all
antibiotic groups. By the positive control, the bacteria count was
not measurable after second dilution step due to massive bacterial
‘slime’. However, after sixth dilution average bacteria count in the
positive control amounted to 49  43 CFU ml1. Negative controls
as well as medium remained negative.
Pseudomonas aeruginosa
OD600 nm after 24-h incubation and prior to soniﬁcation: TSB
after 24-h incubation and before soniﬁcation revealed a mean
OD600 of 0.4  0.4 in the RG and 0.17  0.03 in the NG (P ¼ 0.06).
OD600 nm and bacterial count after soniﬁcation: Mean OD600
after soniﬁcation is illustrated in Fig. 2C. The average count ofFigure 2. Optical density (at 600 nm) of TSB after 24h incubation and after soniﬁcatioadherent bacteria after the second dilution was 1308  252 in the
RG and 8  8 in the NG (P ¼ 0.01). After sixth dilution, the RG
showed 241  127 CFU ml1 and the NG 0 CFU ml1 (P ¼ 0.008).
According to the positive control, bacteria count was not measur-
able after second dilution step; however, after sixth dilution the
average count amounted to 149  200 CFU ml1. Negative controls
as well as medium remained negative.
Escherichia coli
OD600 nm after 24-h incubation and prior to soniﬁcation: Mean
OD600 of the TSB solutionwas 1.7 0.2 in the RG and 0.4 0.1 in the
NG (P ¼ 0.008).
OD600 nm and bacterial count after soniﬁcation: Mean OD600
after soniﬁcation is presented in Fig. 2D. The average count of
adherent bacteria was measured after second and sixth dilution.
After second dilution, the average bacteria count was
294  159 CFU ml1 in the RG and 0.2  0.5 CFU ml1 in the NG
(P ¼ 0.001). The CFUs in the positive control grafts were not
measurable. After sixth dilution, average bacteria count amounted
to 2.4  1.2 in the RG and 0 CFU ml1 in the NG (P ¼ 0.03). The
positive control grafts showed 232  318 CFU ml1 after sixth
dilution. Negative controls and medium remained negative during
all dilution steps.
Viability tests for ECs
The optical as well as the arithmetic results of the viability tests
are illustrated in Fig. 3
Bioﬁlm formation
Bacterial bioﬁlms were visible in all positive controls in SEM. In
Figs. 4e7, we demonstrate the antibacterial effect of the respective
antibiotics compared to positive controls. Concerning Gram-n of the grafts for (A) S. epidermidis, (B) S. aureus, (C) P. aeruginosa and (D) E. coli.
Figure 4. Example of a 24h-old bioﬁlm of S. epidermidis in control group (A), after impregnation with daptomycin (B), rifampin (C) and nebacetin (D). The asterisks show the formed
bioﬁlm with intact organisms and the arrows represent the eliminated bacteria (lysis).
Figure 3. (A) Viable endothelial cells stained with calcein acetoxylmathyl ester under optical microscope (x10 magniﬁcation) after addition of antibiotic-impregnated grafts and 24h
incubation at 37 C and 5% CO2 and (B) Average count of viable endothelial cells after addition of antibiotic-impregnated grafts and 24h incubation (37 C, 5%CO2) reﬂecting the
toxicity of each antibiotic agent.
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bacterial lysis. However, we observed a few number of intact bio-
ﬁlms within the ﬁbres of grafts that were impregnated with
rifampin and nebacetin (Figs. 4 and 5), whereas daptomycin-
impregnated grafts were free from any bioﬁlm. Regarding Gram-
negative micro-organisms, only nebacetin showed successful
elimination of both tested micro-organisms (Figs. 6 and 7). Note-
worthy is that nebacetin led to elimination of E. coli even within
intact bioﬁlms of the micro-organism and even if its characteristic
network had been built (Fig. 7D).
Discussion
Nebacetin consists of two different compounds, neomycin and
bacitracin. Neomycin as aminoglycoside acts on susceptible
bacteria (mostly Gram-negative) presumably by irreversibly
binding to the 30S ribosomal subunit, thereby inhibiting bacterial
protein synthesis.15 Bacitracin is a polypeptide produced by strains
of Bacillus licheniformis and acts against cell-wall synthesis through
inhibition of de-phosphorylation of C55-isoprenyl pyrophosphate,
which is essential for regeneration of the lipid carrier required for
the cyclic synthesis of peptidoglycan. Hence, bacitracin distorts the
membrane structure due to either the removal of the lipids or direct
penetration.16
Our study is the ﬁrst one in English literature testing nebacetin
as impregnation agent for prevention of VGI. Since 1953 both
antibiotics have been widely used for skin and eye infections.17Figure 5. Example of a 24h-old bioﬁlm of S. aureus in control group (A), after impregnation
bioﬁlm with intact organisms and the arrows represent the eliminated bacteria (lysis). Bes
polymeric substance is presented (cross).Neomycin sulphate is indicated for the treatment of superﬁcial
infections, prophylaxis against infection inminor and postoperative
wounds, adjunctive treatment of burns and management of
superinfection in chronic dermatoses, stasis dermatitis or chronic
leg ulcers.18 However, allergic contact dermatitis (1e6% in intact
skin), delayed hypersensitivity or immunoglobulin E (IgE)-medi-
ated reactions and plasmid-mediated resistance have been re-
ported.19 Bacitracin is used for local infections, secondary
pyodermas and as adjunct measure in burn treatment and in
operative wounds.18 Few cases of delayed hypersensitivity, IgE-
mediated allergic reactions or dermatitis have been reported.19
Along with neomycin (nebacetin) led to increased risk of sensiti-
sation in the treatment of chronic ulcers.18 We tested additionally
the toxic effects of nebacetin as well as of the other antibiotic
agents against ECs. ECs are particularly attractive for toxicity tests
representing a sensitive system that maintains several phenotypic
and genotypic characteristics of human cells in vivo.20 Besides, ECs
provide rapid coverage of porous synthetic graft surfaces in contact
with arterial circulation (graft anastomosis).21
The results of our study support the hypothesis that nebacetin is
very effective to eliminate in vitro VGI caused by S. epidermidis,
S. aureus, P. aeruginosa or E. coli. Regarding Gram-positive bacteria,
where several reports advocate the advantageous use of dapto-
mycin, nebacetin also showed comparable efﬁcacy. Rifampin was
not as efﬁcient as expected and additionally was high toxic against
ECs. Furthermore, evaluation of the infected grafts under SEM
conﬁrmed the excellent antibacterial effect of daptomycin (Figs. 4with daptomycin (B), rifampin (C) and nebacetin (D). The asterisks show the formed
ides, in the bioﬁlm of the rifampin-impregnated grafts the characteristic extracellular
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(P. aeruginosa) (Fig. 6). Bioﬁlm remains themost relevant feature for
the pathogenicity of bacteria colonising surgical implants, pro-
tecting them from recognition and elimination through host
defence mechanisms.6
The most common agent causing VGI remains S. epidermidiswith
the characteristic exopolysaccharide bioﬁlm.3,4,8 According to
Edmiston et al., prognostic factors affecting the outcomes of staphy-
lococcal device infections are (1) the composition and structural
characteristics of the biomedical device surface, (2) the selective
activity of the therapeutic agent and (3) the presence or absence of
exopolysaccharide bioﬁlm.22 Hence, several preventive measures
have been developed to optimise penetration of bioﬁlm and to
maintain adequate levels of antibacterial substance into tissue during
the surgical procedure. Common practice is the perioperative use of
antibiotics and the aseptic conditions of surgery.6e8 However, it
remains questionable if both techniques are able to prevent bacterial
adhesion and to penetrate a bioﬁlm over a non-vascularised graft.
Therefore, graft impregnation for local antibiotic release in the peri-
graft tissues has been supported as an advantageous adjuvant tech-
nique, especially in patients having several risk factors for VGI
(autoimmune disease, immunosuppression, diabetes mellitus, corti-
costeroid administration, liver disease/cirrhosis, malnutrition, etc.).23
In this context, encouraging results after the use of antibiotic-
impregnated polymethylmethacrylate beads for the treatment of
experimental prosthetic graft infections support this concept.24
However, considerations for rapid development of antibiotic resis-
tance have been uttered.25 To ﬁeld this issue, Friberg et al.Figure 6. Example of a 24h-old bioﬁlm of P. aeruginosa in control group (A,B), after impregn
intact organisms and the arrows represent the eliminated bacteria (lysis).demonstrated in 1359 patients, undergoing local implantation of
collagen-gentamycin for the prevention of sternal wound infections,
no long-term increase in the absolute incidence of aminoglycoside
resistance agents.25
Notwithstanding on the method of graft impregnation or
coating, the most relevant factor remains the effectiveness of the
antibiotic agent, which should cover, ideally, both Gram-positive
and -negative bacteria. Further relevant parameters are substance
toxicity (systemic and local) and costs of therapy. Rifampin has
a chemical property that easily links to gelatin in a form of ionic
bonding and targets Gram-positive and -negative micro-organ-
isms.26 Regarding the adherence of daptomycin or nebacetin on the
gelatin layer or other matrices of impregnation (e.g., cyclodextrin
polymers) no data are available in English or German literature.
However, antibacterial activity of rifampin has been challenged due
to its effect reduction after brief exposure, especially by staphylo-
coccal infections.8 In contrast, daptomycin is a high-promising new
agent due to its ability to inhibit organisms embedded in bioﬁlms
and to its great antimicrobial activity against resistant micro-
organisms.8 It was approved in 2003 for the non-topical treatment
of skin structure infections caused by Gram-positive pathogens,
includingmethicillin-resistant S. aureus (MRSA) and in 2006 for the
treatment of bacteraemia.27 Disadvantage remains its limited
activity against exclusively Gram-positive bacteria. In this context,
nebacetin is superior to rifampin and daptomycin.
Unclear, however, is whether nebacetin still acts more effec-
tively compared to rifampin or daptomycin combination therapies.
Where Cirioni et al.8 addressed that combination of rifampin andation with rifampin (C) and nebacetin (D). The asterisks show the formed bioﬁlm with
Figure 7. Example of a 24h-old bioﬁlm of E. coli in control group (A,B), after impregnation with rifampin (C) and nebacetin (D). The asterisks show the formed bioﬁlm with intact
organisms and the arrows represent the eliminated bacteria (lysis). Of note in nebacetin-imregnated graft, albeit the characteristic network of the micro-organism (cross) has been
built, all bacteria have been eliminated.
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respective of each single compound, other groups showed indif-
ference or antagonismwhen used against MRSA.28 More promising
results have been published after a combination of rifampin with
linezolid for the treatment of infections caused by S. aureus or
MRSA strains. In these series, linezoliderifampin treatment pre-
vented the emergence of rifampin-resistant mutants.26,28 However,
an overview of the in vitro data for rifampin combination therapies
against staphylococci demonstrated rather antagonism or indif-
ference than synergy.28
Another interesting outcome in this study was the considerably
high toxic effects of rifampin against ECs. Rifampin’s toxicity against
ECs may explain the observed necrosis at the anastomoses in 25% of
gelatin-sealed grafts soakedwith rifampin as reported by Schneider
et al. in a dog model with MRSA and E. coli infection, albeit this
remains a speculation.29 In thatmodel, histological evaluation of the
anastomoses revealed that the necrosis was not due to bacterial
colonisation.29 In anycase, the toxic effectof antibiotics onECsmight
be crucial for the long-term patency, especially in small-calibre
prostheses and this requires further investigation.
We do recognise a number of limitations in our study. We
conducted this in vitro study as a ﬁrst step in order to test an
unknown in vascular surgery antibiotic agent (nebacetin).
However, in vivo analysis is still missing and this underpowers the
outcome of this model. We did not assess emergence of antibiotic
resistance of the micro-organisms and the observation time (24 h)
was short to assess the efﬁcacy of antibiotics against later post-
operative graft colonisation. Although nebacetin and daptomycinshowed comparable efﬁcacy against staphylococcal infections, it
remains unclear if nebacetin is also effective against MRSA. Finally,
bioﬁlms were assessed in a static and not dynamic experimental
model and the possible impact of blood or peritoneal ﬂuid ﬂow on
bioﬁlm formation could not be assessed.
In conclusion, the results of this study support the superiority of
nebacetin for the early prevention of in vitro VGI caused by either
gram-positive or -negative micro-organisms: (1) the more effective
bacterial eradication in comparison to rifampin, (2) the comparable
to daptomycin antibacterial effect against non-resistant staphylo-
coccal infections, (3) the excellent antibacterial activity against
P. aeruginosa and E. coli, (4) the absence of any toxicity against ECs
and, lastly, (5) the combination of two compounds in one antibiotic
agent (lower costs) remain its advantageous characteristics.
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